MetaCap

Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

18.45+0.25 (+1.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DNLI stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.72
52-week range
15.34 – 27.30
Day range
17.92 – 18.85
Volume / Avg
2.63M / 1.68M
Beta
—

52-week range

$15.34$27.30

DNLI stock today

Denali Therapeutics (DNLI) closed at $18.45 on Nov 20, up 1.37% (+$0.25), versus the S&P 500's 3.70% decline. Shares are 32.4% below their 52-week high of $27.30, set on Jul 9, 2026 and 20.3% above the 52-week low of $15.34, in the middle of the past year's range. DNLI is up 11.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 2.5%.

Denali Therapeutics has posted a net loss over the last twelve months (EPS of -$1.72), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Denali Therapeutics

Company profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Ryan J. Watts Ph.D.
Headquarters
South San Francisco, CA
Employees
503
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, Denali Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Denali Therapeutics reported a net loss of $512.5 million, compared with a loss of $422.8 million a year earlier. Diluted earnings per share came in at -$2.97.

Denali Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$330.53M$108.46M$48.66M
Growth—-100.00%+204.74%+122.90%-85.50%
Net income$-512.54M$-422.77M$-145.22M$-325.99M$-290.58M
EPS (diluted)$-2.97$-2.57$-1.06$-2.60$-2.39

Analyst forecast

Forecast

Consensus (21 analysts)

strong_buy

Avg. price target

$35.82+94.15%

  • Strong buy 2
  • Buy 18
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $24.00High $46.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.37 vs $-0.69
Surprise
+153.62%

DNLI news

All DNLI news

Denali Therapeutics peers

Health Care sector
DNLI peer companies
CompanyPrice% ChgMarket capCompare
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs DNLI
VCELVericel Corporation57.52-1.27%$2.94Bvs DNLI
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs DNLI
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs DNLI
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs DNLI
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs DNLI
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs DNLI
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs DNLI

Indexes, lists and sector

Denali Therapeutics stock FAQ

What is Denali Therapeutics's stock price today?

DNLI last traded at $18.45 as of Nov 20, 4:00 PM EST, up 1.37% on the day. Prices are delayed at least 15 minutes.

Who is Denali Therapeutics's CEO?

Dr. Ryan J. Watts Ph.D. is the chief executive officer of Denali Therapeutics Inc., which has about 503 employees.

What is the DNLI 52-week high?

The 52-week high for DNLI is $27.30 and the 52-week low is $15.34. The stock is currently 32.4% below its high.

Compare DNLI